Togo: Medicines Regulator Creation Decree Establishes New Agency

• Togo's government adopted a decree on September 7, 2026, to establish the National Agency for the Regulation of Medicines and Other Healthcare Products.
• This autonomous agency will be responsible for regulating, supervising, and monitoring the nationwide market for medicines and healthcare products.
• The creation aims to strengthen quality control, pharmaceutical inspections, and market surveillance, addressing existing institutional and operational challenges.
• A key objective is to combat the persistent problem of substandard and falsified medicines, an issue previously discussed by authorities in June 2025.
• The reform responds to an expanding pharmaceutical market and regional reliance on imported medicines, which exposes the country to supply-chain risks.

The creation of the National Agency for the Regulation of Medicines Togo is a direct response to these identified shortcomings, aiming to implement a more rigorous Togo pharmaceutical market regulation and a robust Togo drug quality control law to safeguard public health.

The government of Togo has officially moved to establish a new regulatory authority for medicines and other healthcare products, adopting a decree on Monday, September 7, 2026. This Togo medicines regulator creation decree, approved during a Council of Ministers meeting in Lomé, outlines the foundational elements for the National Agency for the Regulation of Medicines and Other Healthcare Products. The comprehensive decree details the agency's establishment, its core responsibilities, organizational structure, and operational procedures, setting the stage for a significant shift in the nation's healthcare sector.

This newly formed entity will operate as an autonomous body, tasked with broad oversight across the country. Its mandate encompasses the regulation, supervision, and ongoing monitoring of the entire market for medicines and other healthcare products. Government officials anticipate that the agency will play a crucial role in strengthening quality control measures, enhancing pharmaceutical inspections, and improving market surveillance. Furthermore, it is expected to foster better coordination among various stakeholders within the industry, streamlining processes and ensuring greater accountability in Togo's healthcare product oversight.

The establishment of this agency comes at a critical juncture for Togo, as its pharmaceutical market experiences rapid expansion, marked by an increasing diversity of products and a growing number of participants across the supply and distribution chains. Despite this growth, the nation's existing regulatory system has faced persistent institutional, technical, and operational challenges. These systemic issues have historically hampered effective quality control, thorough inspections, robust market surveillance, and comprehensive pharmacovigilance efforts.

A significant concern that the new agency aims to tackle is the pervasive problem of substandard and falsified medicines. This issue not only poses substantial public health risks but also undermines consumer trust and market integrity. Recognizing the gravity of this challenge, Togolese authorities and lawmakers initiated discussions in June 2025 to strengthen the legal framework specifically targeting falsified medicines. The creation of the National Agency for the Regulation of Medicines Togo is a direct response to these identified shortcomings, aiming to implement a more rigorous Togo pharmaceutical market regulation and a robust Togo drug quality control law to safeguard public health.

The challenges faced by Togo's pharmaceutical sector are not unique but reflect a broader regional vulnerability. The West African region, for instance, is heavily reliant on external sources, importing an estimated 70% to 90% of the medicines it consumes. This high dependency on foreign suppliers exposes national markets to significant supply-chain risks and makes them particularly susceptible to the influx of unregulated or illicit products.

By establishing a dedicated and autonomous regulator, Togo is taking a decisive step to enhance its internal capacity for oversight and control. This move is expected to bolster the nation's resilience against external market fluctuations and the proliferation of harmful products, thereby strengthening its overall Togo falsified medicines framework. The agency's comprehensive approach to regulation, supervision, and monitoring is poised to set a new standard for healthcare product safety and efficacy within the country and potentially serve as a model for regional partners.

Lawyers advising pharmaceutical companies, healthcare product manufacturers, or distributors operating in Togo must monitor the new agency's forthcoming regulations and enforcement actions to ensure client compliance with enhanced quality control, inspection, and market surveillance requirements. This development signals a stricter regulatory environment for the sector.

Source: Original reporting via {source}